Key Factor Supporting Acute Coronary Syndrome Market Development in 2025: Rising Prevalence Of Chronic Diseases Fuels Growth In The Acute Coronary Syndrome Market

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

How Large Will the Acute Coronary Syndrome Market Size By 2025?
The market size for acute coronary syndrome has seen significant expansion in the past few years. By 2025, it is projected to increase to $10.5 billion from $9.86 billion in 2024, demonstrating a compound annual growth rate (CAGR) of 6.5%. The previous period's growth can be associated with efforts in public health, the use of telemedicine and remote monitoring, enhanced emergency medical facilities, and a heightened demand for patient education.

How Big Is the Acute Coronary Syndrome Market Size Expected to Grow by 2029?
Anticipated to experience significant expansion in the upcoming years, the acute coronary syndrome market is predicted to escalate to a value of $13.3 billion by 2029, progressing at a compound annual growth rate (CAGR) of 6.1%. The factors contributing to this growth during the forecast period include a rising demand for bespoke medicine, a surge in interventional cardiology, heightened awareness, and an aging global population. Key trends during the forecast period consist of progressions in diagnostic equipment, the incorporation of health information technology, swift response mechanisms, and technological advancements.

View the full report here:
https://www.thebusinessresearchcompany.com/report/acute-coronary-syndrome-global-market-report

Which Key Market Drivers Powering Acute Coronary Syndrome Market Expansion and Growth?
The rise in chronic conditions such as coronary artery disease, ischemic heart disease, and various vascular diseases is predicted to boost the expansion of the acute coronary syndrome market for the future. Ischemic heart disease, a long-lasting ailment triggered by blockages or constrictions in the coronary arteries, will contribute significantly. The therapeutic approach to acute coronary syndrome (ACS) prioritizes the immediate reduction of symptoms, minimization of cardiac damage, and prevention of additional complications in patients. For example, a study published in the Journal of the American College of Cardiology in August 2022 highlighted that all four cardiovascular risk factors are predicted to augment among the average U.S. population between 2025 and 2060. The rates of dyslipidemia and hypertension are expected to rise by 27.6% and 25.1% respectively. The projected rise in heart failure (33.4%) and ischemic heart disease (30.7%) dominates, followed by heart attacks (16.9%) and strokes (33.8%). Consequently, the spread of chronic diseases like coronary artery disease, ischemic heart disease, and vascular diseases propels the acute coronary syndrome market. Acute Coronary Syndrome Market Driver: Escalating Health Care Expenditures Cultivates Advancement in Coronary Syndrome Treatment

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12985&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Acute Coronary Syndrome Market?
Leading firms in the acute coronary syndrome market are forming novel medications for the treatment of acute coronary syndrome, in an effort to maintain their market standing. The refinement of drug development could potentially enhance the efficacy of ACS treatments, thus optimizing the time and assets needed per patient. For example, in June 2023, AGEPHA Pharma USA LLC, a company based in the US that specializes in pharmaceuticals, rolled out Lodoco. This was greenlit by the US government agency, the Food and Drug Administration (FDA). This serves as the first ever anti-inflammatory atheroprotective cardiovascular therapeutic designed to lower risks of heart stroke, coronary revascularization, myocardial infarction (MI) and cardiovascular death amongst adult patients with cardiovascular diseases, including acute coronary syndrome.

What Are the Emerging Segments in the Acute Coronary Syndrome Market?
The acute coronary syndrome market covered in this report is segmented -

1) By Type: Non-St-Elevation Myocardial Infarction, St-Elevation Myocardial Infarction, Unstable Angina
2) By Treatment: Medications, Statins, Beta blockers, ACE inhibitors, Anticoagulants, Other Treatment
3) By Diagnosis: Stress Test, Blood Tests, Imaging, Other Diagnosis
4) By Route Of Administration: Oral, Parenteral
5) By End-User: Hospitals, Specialty clinics, Other End User

Subsegments:
1) By Non-ST-Elevation Myocardial Infarction: Medical Management, Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Grafting (CABG)
2) By ST-Elevation Myocardial Infarction: Medical Management, Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Grafting (CABG)
3) By Unstable Angina: Medical Management, Percutaneous Coronary Intervention (PCI), Coronary Artery Bypass Grafting (CABG)

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12985&type=smp

Who Are the Global Leaders in the Acute Coronary Syndrome Market?
Major companies operating in the acute coronary syndrome market are Pfizer Inc., Johnson and Johnson Limited, Siemens AG, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, Medtronic PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Co Ltd., Stryker Corporation, GE Healthcare Inc., Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Terumo Corp., BioMérieux SA, Beckman Coulter Inc., Quidel Corporation, Bio-Rad Laboratories Inc., Biotronik Inc., Randox Laboratories Limited, Nihon Kohden Corporation, Trinity Biotech plc.

Which are the Top Profitable Regional Markets for the Acute Coronary Syndrome Industry?
North America was the largest region in the acute coronary syndrome market in 2024. The regions covered in acute coronary syndrome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12985

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.